MRA: FDA accepts four new States
After a positive assessment, the US Food and Drug Administration (FDA) has approved four additional EU Member States to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
In November 2018, the FDA confirmed the capability of Belgium, Denmark, Finland and Latvia. This means that the FDA can now rely on a total of 19 Member States to replace their own inspections - in addition to those mentioned these are:Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Related GMP News
12.02.2025Warning Letter for Big Pharma Company: Root Cause Analysis a Topic
05.02.2025Inadequate Analytical and Microbiological Controls - FDA Warning Letter to Indian Company
29.01.2025FDA Warning Letter to Chinese Manufacturer of OTC Products
29.01.2025Warning Letter - No Testing for EC/DEG and other Deficiencies
08.01.2025PIC/S publishes Guidance Documents on Remote Assessments
04.12.2024Discarded Batch Documentation again found during Inspection